CT
Cameron Turtle (Chief Executive Officer) filed 11 Form 4 reports in the trailing twelve months (0 purchases, 11 sales), most often in Spyre Therapeutics, Inc. (SYRE). The largest single filing was $1.4M of SYRE (14,184 sh across 3 lots, as filed), executed Aug 3. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
11
0 buys · 11 sells
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$9.9M
shares × price, as filed
Last traded
Oct 1
Filed Oct 2
Median ADV $134.1M across their filed names
Open performance→Volume by month
Buys $0
Sells $10.9M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
11 filings
Sector per market data · by filing · past 12 months
Most traded names
SYRERecent filings
SYRESALE
Spyre Therapeutics, Inc.
View filing →
$1.3M14,300 sh across 4 lots
Exec Oct 1
Filed Oct 2 · 9:29 PM ET SYRESALE Spyre Therapeutics, Inc. View filing → $1.3M
14,600 sh across 3 lots
Exec Sep 1
Filed Sep 3 · 9:33 PM ET SYRESALE Spyre Therapeutics, Inc. View filing → $1.4M
14,184 sh across 3 lots
Exec Aug 3
Filed Aug 5 · 9:31 PM ET SYRESALE Spyre Therapeutics, Inc. View filing → $1.3M
14,410 sh across 2 lots
Exec Jul 1
Filed Jul 2 · 9:32 PM ET SYRESALE Spyre Therapeutics, Inc. View filing → $1.1M
15,000 sh across 3 lots
Exec Jun 1
Filed Jun 3 · 5:30 PM ET SYRESALE Spyre Therapeutics, Inc. View filing → $976K
13,700 sh across 4 lots
Exec May 1
Filed May 1 · 5:30 PM ET SYRESALE Spyre Therapeutics, Inc. View filing → $740K
15,000 sh across 2 lots
Exec Apr 1
Filed Apr 3 · 5:30 PM ET SYRESALE Spyre Therapeutics, Inc. View filing → $633K
15,000 sh across 2 lots
Exec Mar 2
Filed Mar 3 · 5:30 PM ET More filings →